share_log

Lake Street Assumes Biolase at Buy, Announces Price Target of $1.5

Lake Street Assumes Biolase at Buy, Announces Price Target of $1.5

湖街假設生物化發現買入,宣布目標價為 1.5 美元
Benzinga Real-time News ·  2023/01/20 08:58

Lake Street analyst Frank Takkinen assumes Biolase (NASDAQ:BIOL) with a Buy rating and announces Price Target of $1.5.

Lake Street分析師Frank Takkinen假設Biolase(納斯達克:BIOL)的評級為買入,並宣佈目標價為1.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論